| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.09 | 0.6 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | 0.077 | 0.6 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |